Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,528,156
  • Shares Outstanding, K 46,482
  • Annual Sales, $ 7,420 K
  • Annual Income, $ -59,780 K
  • 60-Month Beta 3.06
  • Price/Sales 333.86
  • Price/Cash Flow N/A
  • Price/Book 13.82
Trade CLDX with:

Options Overview

Details
  • Implied Volatility 83.34%
  • Historical Volatility 23.84%
  • IV Percentile 27%
  • IV Rank 10.94%
  • IV High 219.98% on 03/26/21
  • IV Low 66.56% on 11/19/20
  • Put/Call Vol Ratio 0.30
  • Today's Volume 882
  • Volume Avg (30-Day) 544
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 6,011
  • Open Int (30-Day) 5,884

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.36
  • Number of Estimates 2
  • High Estimate -0.34
  • Low Estimate -0.37
  • Prior Year -0.36
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.96 +23.73%
on 08/18/21
56.17 -3.17%
on 09/10/21
+8.92 (+19.62%)
since 08/17/21
3-Month
26.80 +102.92%
on 06/18/21
56.17 -3.17%
on 09/10/21
+26.39 (+94.25%)
since 06/17/21
52-Week
11.55 +370.91%
on 09/24/20
56.17 -3.17%
on 09/10/21
+42.28 (+349.13%)
since 09/17/20

Most Recent Stories

More News
Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study

Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.

NVS : 83.48 (-1.07%)
RHHBY : 46.0700 (-1.60%)
MRK : 71.68 (-0.40%)
CLDX : 54.39 (+2.08%)
Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized...

CLDX : 54.39 (+2.08%)
Chart of the Day: Celldex: Leader in Monoclonal Research

The Barchart Chart of the Day belongs to the healthcare company Celldex Therapeutics (NASDAQ: CLDX ). I found the stock by sorting Barchart's Top Stocks to Own list first by the most frequent number...

CLDX : 54.39 (+2.08%)
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CLDX : 54.39 (+2.08%)
Celldex: Q2 Earnings Snapshot

HAMPTON, N.J. (AP) _ Celldex Therapeutics Inc. (CLDX) on Thursday reported a loss of $13.4 million in its second quarter.

CLDX : 54.39 (+2.08%)
Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 -

CLDX : 54.39 (+2.08%)
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Therapeutics, Inc. ("Celldex" or the "Company") (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 6,845,238 shares of its common stock, which...

CLDX : 54.39 (+2.08%)
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More

The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).

BIIB : 300.19 (+0.17%)
NVO : 101.41 (-0.95%)
AMGN : 219.38 (+0.93%)
CLDX : 54.39 (+2.08%)
PRTA : 77.07 (+3.05%)
SGTX : 6.11 (+0.49%)
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data

Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.

NVS : 83.48 (-1.07%)
RHHBY : 46.0700 (-1.60%)
MRK : 71.68 (-0.40%)
CLDX : 54.39 (+2.08%)
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock

Celldex Therapeutics, Inc. ("Celldex" or the "Company") (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price...

CLDX : 54.39 (+2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 59.54
2nd Resistance Point 57.82
1st Resistance Point 56.11
Last Price 54.39
1st Support Level 52.68
2nd Support Level 50.96
3rd Support Level 49.25

See More

52-Week High 56.17
Last Price 54.39
Fibonacci 61.8% 39.13
Fibonacci 50% 33.86
Fibonacci 38.2% 28.59
52-Week Low 11.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar